论文部分内容阅读
目的研究瑞巴派特在体胃肠道吸收动力学的特征。方法采用大鼠胃部定时取样和单向肠灌流技术,HPLC法测定瑞巴派特的含量,对瑞巴派特在大鼠胃部和不同肠段吸收进行研究。结果在0~120 min,大鼠胃部吸收呈线性吸收规律,120 min后胃中平均吸收率为28.47%;瑞巴派特在不同肠段的净累计吸收量为十二指肠>空肠>回肠>结肠,并与瑞巴派特吸收速率常数Ka顺序保持一致;瑞巴派特在20~100μg·ml-1对小肠吸收速率常数Ka无影响。结论瑞巴派特为全胃肠道吸收药物,以胃和十二指肠为主要吸收部位,提示瑞巴派特可以设计制成缓控释制剂。
Objective To study the characteristics of rebamipide absorption in the body and gastrointestinal tract. Methods Gastric time sampling and unilateral intestinal perfusion technique were used in rats. The contents of rebamipide were determined by HPLC, and the absorption of rebamipide in the stomach and intestine of rats was studied. Results At 0 ~ 120 min, the absorption of stomach in rats showed a linear pattern of absorption. The average absorption rate in stomach after 120 min was 28.47%. The net absorption of rebamipide in different segments of intestine was duodenum> jejunum> Ileum> colon, and consistent with the rebamiprid absorption rate constant Ka sequence; rebamipide at 20 ~ 100μg · ml-1 on the intestinal absorption rate constant Ka had no effect. Conclusion Rebamipide is a total gastrointestinal absorption drug with stomach and duodenum as its main absorption sites, suggesting that rebamipide can be designed as a controlled release formulation.